1985
DOI: 10.1016/s0092-8674(85)80078-7
|View full text |Cite
|
Sign up to set email alerts
|

HTLV-III env gene products synthesized in E. coli are recognized by antibodies present in the sera of AIDS patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
44
0

Year Published

1986
1986
2007
2007

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 77 publications
(44 citation statements)
references
References 17 publications
0
44
0
Order By: Relevance
“…The replication of equine infectious anemia virus, for example, progresses through cycles in infected horses, with each peak in virus replication reflecting a change in the antigenicity of its envelope glycoprotein (21). Similarly, five independent isolates of the acquired immune deficiency syndrome retrovirus all display striking sequence heterogeneity in the external region of the envelope glycoprotein, indicating that random mutation followed by a positive selection for varients which can escape immune detection may have occurred (9).…”
Section: Resultsmentioning
confidence: 99%
“…The replication of equine infectious anemia virus, for example, progresses through cycles in infected horses, with each peak in virus replication reflecting a change in the antigenicity of its envelope glycoprotein (21). Similarly, five independent isolates of the acquired immune deficiency syndrome retrovirus all display striking sequence heterogeneity in the external region of the envelope glycoprotein, indicating that random mutation followed by a positive selection for varients which can escape immune detection may have occurred (9).…”
Section: Resultsmentioning
confidence: 99%
“…Rather, the goal of this study was to localize T-cell sites from the HIV envelope that might be useful in vaccine development, as, to our knowledge, no T-cell epitopes have been identified in any AIDS virus protein. Studies with AIDS virus peptides have been directed at antibody specificities (1)(2)(3)(4)(5)(6)(7)(8)(9) or pharmacologic blocking of gpl20 binding to CD4 (51) and have dealt with sites distinct from those of the present study.…”
Section: Discussionmentioning
confidence: 99%
“…Transcripts expressed from this vector possess a 90-nt poly(A) sequence near their 3Ј ends, followed by a 31-nt non-A extension. Plasmid pRSV-Rev contains the Rev coding region from HIV-1 and is driven by the Rous sarcoma virus long terminal repeat promoter (6). PyE is the entire polyomavirus genome cloned into pUC18 at the BamHI site.…”
Section: Methodsmentioning
confidence: 99%